Cyclo Therapeutics (CYTH) - רווח נקי למניה (EPS TTM)

Cyclo Therapeutics (CYTH) is building an ecosystem of cyclodextrin-based drugs and holds FDA breakthrough therapy designation. Partnerships with institutes are accelerating the development of the drug Trappsol Cyclo. The trailing 12-month EPS on the GURU.Markets chart demonstrates that the metric remains at -0.90. Cyclo Therapeutics is diversifying its risks by focusing on the treatment of rare genetic pathologies of the brain and blood vessels.

This indicator measures the portion of net income attributable to a single common share, reflecting the actual efficiency of capital generation. By analyzing the trailing twelve-month earnings per share, an investor can observe current business dynamics without the delays associated with quarterly reporting. The calculation is based on the sum of profits over the last 12 months, adjusted for the total number of securities. For Cyclo Therapeutics (CYTH), the stability of this metric is supported by long-term agreements with international laboratories. Reliable supply chain logistics for chemical compounds minimize operational risks, ensuring the predictability of financial results.